Alpha 2.0
Login Register
» Authors » Devalingam Mahalingam

Devalingam Mahalingam

Explore the profile of Devalingam Mahalingam including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 99
Citations 2711
Followers 0
Related Specialties
Oncology
Pharmacology
Cell Biology
Top 10 Co-Authors
John Sarantopoulos
Francis J Giles
Steffan T Nawrocki
Joel Michalek
Ronan Swords
Kevin Kelly
Monica M Mita
Jennifer S Carew
Francis Giles
Kevin R Kelly
Published In
Clin Cancer Res
Oncotarget
Cancers (Basel)
J Gastrointest Oncol
Cancer Chemother Pharmacol
Affiliations
Soon will be listed here.
Recent Articles
11.
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
Carneiro B, Cavalcante L, Mahalingam D, Saeed A, Safran H, Ma W, et al.
Clin Cancer Res . 2023 Nov; 30(3):522-531. PMID: 37982822
Purpose: The safety, pharmacokinetics, and efficacy of elraglusib, a glycogen synthase kinase-3β (GSK-3β) small-molecule inhibitor, as monotherapy or combined with chemotherapy, in patients with relapsed or refractory solid tumors or...
12.
Correction: Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer
Mahalingam D, Hanni S, Serritella A, Fountzilas C, Michalek J, Hernandez B, et al.
Oncotarget . 2023 Oct; 14:890-892. PMID: 37861386
No abstract available.
13.
Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC)
Mahalingam D, Chen S, Xie P, Loghmani H, Heineman T, Kalyan A, et al.
Br J Cancer . 2023 Jul; 129(5):782-790. PMID: 37443348
Background: We previously reported activity of pelareorep, pembrolizumab and chemotherapy. Patients developed new T-cell clones and increased peripheral T-cell clonality, leading to an inflamed tumour. To evaluate a chemotherapy-free regimen,...
14.
Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer
Mahalingam D, Hanni S, Serritella A, Fountzilas C, Michalek J, Hernandez B, et al.
Oncotarget . 2023 Jun; 14:622-636. PMID: 37335291
Background: Androgen deprivation therapy (ADT) can lead to metabolic syndrome (MS) and is implicated in ADT-resistance. Metformin showed antineoplastic activity through mTOR inhibition secondary AMPK-activation. Materials And Methods: To investigate...
15.
Neoadjuvant therapy use and association with postoperative outcomes and overall survival in patients with extrahepatic cholangiocarcinoma
Silver C, Joung R, Logan C, Benson A, Mahalingam D, DAngelica M, et al.
J Surg Oncol . 2022 Oct; 127(1):90-98. PMID: 36194064
Background And Objectives: Evidence for neoadjuvant therapy (NAT) in extrahepatic cholangiocarcinoma (eCCA) is limited. Our objectives were to: (1) characterize treatment trends, (2) identify factors associated with receipt of NAT,...
16.
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
Zhou X, Vaishampayan U, Mahalingam D, Harvey R, Chung K, Sedarati F, et al.
Invest New Drugs . 2022 Aug; 40(5):1042-1050. PMID: 35932388
Pevonedistat (TAK-924/MLN4924) is an investigational small molecule inhibitor of the NEDD8-activating enzyme that has demonstrated clinical activity across solid tumors and hematological malignancies. Here we report the results of a...
17.
A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01
Sahai V, Griffith K, Beg M, Shaib W, Mahalingam D, Zhen D, et al.
Cancer . 2022 Jul; 128(19):3523-3530. PMID: 35895381
Background: Gemcitabine and cisplatin has limited benefit as treatment for advanced biliary tract cancer (BTC). The addition of an anti-programmed death receptor (PD-1)/PD-ligand (L1) antibody to either systemic chemotherapy or...
18.
Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience
Gerratana L, Movarek M, Wehbe F, Katam N, Mahalingam D, Donahue J, et al.
JCO Precis Oncol . 2022 Jun; 6:e2100289. PMID: 35772051
Purpose: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for baseline characterization and longitudinal monitoring of a tumor throughout disease management. The aim of this study was...
19.
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)
Arora S, Tenner L, Sarantopoulos J, Morris J, Liu Q, Mendez J, et al.
Br J Cancer . 2022 Jun; 127(6):1153-1161. PMID: 35739299
Background: In metastatic colorectal cancer (mCRC), regorafenib (RGF), a multi-kinase inhibitor with angiogenic inhibition has modest effects on survival. We reported that autophagy modulation using hydroxychloroquine (HCQ), enhances the anticancer...
20.
Yttrium-90 Radioembolization of Unresectable Intrahepatic Cholangiocarcinoma: Long-Term Follow-up for a 136-Patient Cohort
Gupta A, Gordon A, Gabr A, Kalyan A, Kircher S, Mahalingam D, et al.
Cardiovasc Intervent Radiol . 2022 Jun; 45(8):1117-1128. PMID: 35732931
Purpose: Unresectable intrahepatic cholangiocarcinoma (ICC) signifies a poor prognosis with limited treatment options beyond systemic chemotherapy. This study's purpose was to evaluate the safety, efficacy, and potential for downstaging to...